skip to content
Primary navigation


Drug - Egaten® (triclabendazole) [Novartis Pharmaceuticals Corporation]

January 2020

Therapeutic area - Anthelmintics

Approval criteria

  • Patient is ≥ 6 years of age; AND
  • Patient has diagnosis of fascioliasis (infection secondary to Fasciola hepatica or Fasciola gigantica); AND
  • Infection has been confirmed by a diagnostic or laboratory test (e.g., imaging scans, stool, bile specimens); AND
  • Patient does not have known hypersensitivity to triclabendazole, excipient ingredients of Egaten or other benzimidazole derivatives; AND
  • Prescriber attestation that he/she will monitor electrocardiogram (ECG) if patient has history of QT prolongation, symptoms consistent with QT prolongation, or if will be used concurrently with QT-prolongating drugs.

Quantity limits

  • 20 mg/kg/24 hour, rounded to the nearest 250 mg tablet
  • Patient’s weight (in kg) must be provided at time of request


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top